(AMG 228) 20140131

Phase: 
I

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects with Selected Advanced Solid Tumors

The purpose of this study is to find out more about the effects of AMG 228 in people that have advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. AMG 228 is an experimental drug that is being developed to stimulate the body’s immune system to kill cancer cells. This study is the first to test AMG 228 in people. This study will look at what doses of AMG 228 are safe for people to take and whether it causes any side effects.

Are you Eligible? (Inclusion Criteria)

Participants must have a confirmed diagnosis of advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer for which no established standard therapy for given tumor type is available or have been intolerant to such therapy.

Specialty Area(s)

Trial Location

West 168th Street
New York, NY 10032
United States